High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells
- PMID: 1909699
- PMCID: PMC12200515
- DOI: 10.1007/BF01612762
High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells
Abstract
Adherent lymphokine-activated killer cells (A-LAK) are highly potent cytotoxic cells, which are shown to be derived not only from natural killer (NK)/K cells but phenotypically also from T cells. The generation and phenotypical and functional characterisation of these T-cell-derived A-LAK are described. In contrast to non-adherent cells (NA-LAK) and unseparated LAK (UN-LAK), these mostly CD3+ CD56+ CD8+ cells display a high degree of expansion following initial interleukin-2 (rIL-2) activation and further culturing in autologous conditioned medium. A comparison of cytotoxic activities of cultured cells reveals a significantly higher oncolytic ability of A-LAK cells against both K562 and Daudi cells than that of cultured controls of NA-LAK and UN-LAK. In addition, A-LAK are characterised by a marked endogenous cytokine release of interferon gamma, tumour necrosis factor alpha and IL-6 as well as by their shedding of p55 IL-2 receptor after exposure to IL-2. The results demonstrate A-LAK to be the lymphocyte subpopulation with the most cytotoxic activity and endogenous cytokine release after exposure to IL-2. The improvement of techniques for long-term cultures may be of interest for future therapeutic approaches.
Similar articles
-
Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.J Cancer Res Clin Oncol. 1997;123(9):478-84. doi: 10.1007/BF01192201. J Cancer Res Clin Oncol. 1997. PMID: 9341896 Free PMC article.
-
Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.J Cancer Res Clin Oncol. 1997;123(8):420-8. doi: 10.1007/BF01372545. J Cancer Res Clin Oncol. 1997. PMID: 9292704 Free PMC article.
-
Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.J Cancer Res Clin Oncol. 1994;120(7):383-8. doi: 10.1007/BF01240135. J Cancer Res Clin Oncol. 1994. PMID: 7514604 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
Cited by
-
In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.Cancer Immunol Immunother. 1994 May;38(5):304-10. doi: 10.1007/BF01525508. Cancer Immunol Immunother. 1994. PMID: 8162612 Free PMC article. Clinical Trial.
-
Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.Cancer Immunol Immunother. 1994 Nov;39(5):305-12. doi: 10.1007/BF01519983. Cancer Immunol Immunother. 1994. PMID: 7987862 Free PMC article.
References
-
- Bergmann L (1990) The clinical significance of IL-2. Onkologie 13:416–422 - PubMed
-
- Bergmann L, Mitrou PS, Weidmann E, Schmidt-Mathiesen A, Hanke P, Hoelzer D (1989) In vitro and in vivo induction of lymphokine activated killer (LAK) cells in patients with gastric cancer and other solid tumors. In: Koldovsky et al. (eds) Lymphokines in cancer. Springer, Berlin Heidelberg New York, pp 32–43
-
- Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS (1990a) Influence of various cytokines on the induction of lymphocyte activated killer (LAK) cells. Nat Immun Growth Regul 9:256–273 - PubMed
-
- Bergmann L, Keilholz U, Bartsch U, Weidmann E, Runne U, Mitrou PS (1990b) Combination of interleukin-2 and interferon-alpha in the treatment of advanced renal cell carcinoma and malignant melanoma. Study design and preliminary results. Onkologie 11:137–140 - PubMed
-
- Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Gianella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, Peschle C (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocate activation following high-dose interleukin-2 bolus treatment. Cancer Res 50:5795–5800 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials